

## REMARKS

This submission is in response to the Office communication mailed May 12, 2009, which stated that "The replies filed on 10/2/08 and 2/13/09 are not fully responsive to the prior office action because of the following omission(s) or matter(s): in the reply dated 10/2/09 claim 36 is added as a new claim. Claim 36 recites a sequence with 4 specifically defined amino acids ... and thus based on 37 CFR 1.821 requires a SEQ ID and sequence listing.

Applicants thank Examiner Niebauer for the interview held today in which Examiner Niebauer clarified that a new sequence listing is not required and requested that claims 24 and 25 be amended to specify the amino acids at positions 19-21 in the sequence recited therein as Xaa's and to define the amino acids as being absent. Applicants have amended claims 24 and 25 as requested by the Examiner. Applicants therefore submit that the application complies with 37 CFR 1.821.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 11, 2009

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097